Cognex (NASDAQ:CGNX - Get Free Report) released its quarterly earnings data on Wednesday. The scientific and technical instruments company reported $0.34 EPS for the quarter, beating analysts' consensus estimates of $0.25 by $0.09, FiscalAI reports. The company had revenue of $268.44 million during the quarter, compared to the consensus estimate of $245.98 million. Cognex had a net margin of 11.51% and a return on equity of 9.02%. Cognex updated its Q2 2026 guidance to 0.400-0.440 EPS.
Cognex Price Performance
Shares of NASDAQ:CGNX traded up $3.43 during mid-day trading on Wednesday, reaching $62.26. 6,817,557 shares of the company were exchanged, compared to its average volume of 2,124,689. The firm has a market cap of $10.40 billion, a price-to-earnings ratio of 92.93 and a beta of 1.48. The firm's 50-day simple moving average is $52.39 and its 200 day simple moving average is $44.95. Cognex has a 1 year low of $27.82 and a 1 year high of $63.01.
Cognex Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Thursday, February 26th were given a dividend of $0.085 per share. The ex-dividend date of this dividend was Thursday, February 26th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 0.5%. Cognex's dividend payout ratio (DPR) is presently 50.75%.
Insider Buying and Selling
In related news, Director Angelos Papadimitriou sold 4,150 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $55.58, for a total transaction of $230,657.00. Following the completion of the transaction, the director owned 16,222 shares of the company's stock, valued at approximately $901,618.76. This trade represents a 20.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Laura Ann Macdonald sold 14,881 shares of the stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $57.16, for a total transaction of $850,597.96. Following the transaction, the vice president directly owned 2,212 shares of the company's stock, valued at $126,437.92. The trade was a 87.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 196,083 shares of company stock valued at $11,419,321. Company insiders own 1.70% of the company's stock.
Hedge Funds Weigh In On Cognex
A number of hedge funds have recently made changes to their positions in CGNX. Royal Bank of Canada boosted its position in shares of Cognex by 13.2% during the 1st quarter. Royal Bank of Canada now owns 200,351 shares of the scientific and technical instruments company's stock worth $5,976,000 after purchasing an additional 23,326 shares during the period. Empowered Funds LLC purchased a new position in Cognex in the 1st quarter valued at approximately $291,000. Intech Investment Management LLC boosted its position in Cognex by 24.1% in the 1st quarter. Intech Investment Management LLC now owns 47,444 shares of the scientific and technical instruments company's stock valued at $1,415,000 after buying an additional 9,223 shares during the period. Geneos Wealth Management Inc. boosted its position in Cognex by 402.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 919 shares of the scientific and technical instruments company's stock valued at $27,000 after buying an additional 736 shares during the period. Finally, Cetera Investment Advisers boosted its position in Cognex by 7.5% in the 2nd quarter. Cetera Investment Advisers now owns 13,208 shares of the scientific and technical instruments company's stock valued at $419,000 after buying an additional 920 shares during the period. Hedge funds and other institutional investors own 88.12% of the company's stock.
Wall Street Analyst Weigh In
CGNX has been the subject of several analyst reports. Robert W. Baird set a $55.00 price target on shares of Cognex in a research note on Tuesday, February 17th. Needham & Company LLC increased their price target on shares of Cognex from $47.00 to $67.00 and gave the company a "buy" rating in a research note on Thursday, February 12th. TD Cowen reissued a "buy" rating on shares of Cognex in a research note on Tuesday, February 17th. Barclays increased their price target on shares of Cognex from $61.00 to $64.00 and gave the company an "overweight" rating in a research note on Monday, March 16th. Finally, DA Davidson set a $55.00 price target on shares of Cognex and gave the company a "neutral" rating in a research note on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $59.50.
Check Out Our Latest Stock Analysis on CGNX
Cognex Company Profile
(
Get Free Report)
Cognex Corporation is a leading provider of machine vision systems, software, sensors and industrial barcode readers used to automate manufacturing, logistics and distribution processes. The company designs and develops vision-based products that help manufacturers and logistics operators inspect, identify and guide parts, assemblies and packaged goods in real time. Its solutions are applied in a broad range of industries, including automotive, electronics, semiconductor, pharmaceutical, food and beverage, and general manufacturing.
The company's product portfolio includes stand-alone vision systems, vision sensors and deep learning-based software platforms that enable automated inspection, quality control and traceability.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cognex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cognex wasn't on the list.
While Cognex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
